Effect and Mechanism of EGFL7 Downregulation in Human Osteosarcoma Cells on the Biological Function of Co-cultured HUVEC

Abstract

Osteosarcoma is the most frequently occurring solid bone cancer with the second highest cancer-related mortality in pediatric patients. Even though epidermal growth factor-like domain 7 is known to be overexpressed in osteosarcoma and is associated with poor clinical outcome, few reports are available regarding its mechanism. Epidermal growth factor-like domain 7-knockdown U2OS cells inhibit the migration, adhesion, and angiogenesis of co-cultured human umbilical vein endothelial cells by diminishing phosphoinositide 3-kinase, Akt signaling pathway activity and vascular endothelial growth factor expression Background: Even though epidermal growth factor-like domain 7 is known to be overexpressed in osteosarcoma and is associated with poor clinical outcome, few reports are available regarding its mechanism.Aims: The objective of this study was to explore the effect and mechanism of downregulating epidermal growth factor-like domain 7 expression in a human osteosarcoma cell line on the biological function of co-cultured human umbilical vein endothelial cells.Study Design: Cell study.Methods: In the present study, human osteosarcoma cell lines U2OS, Saos-2, HOS, and MG63, and normal human osteoblasts were cultured in Dulbecco’s Modified Eagle Medium containing 10% fetal bovine serum and 1x antibiotics at 37 °C and 5% CO2 in an incubator. Of the four osteosarcoma cell lines, U2OS expresses the highest level of epidermal growth factor-like domain 7 mRNA as determined using quantitative reverse transcription polymerase chain reaction. With the knockdown of epidermal growth factor-like domain 7 in U2OS and human umbilical vein endothelial cells by lentivirus, the proliferation and apoptosis of U2OS and human umbilical vein endothelial cells were investigated using MTT and flow cytometry assays. After the co-culture of human umbilical vein endothelial cells and epidermal growth factor-like domain 7-knockdown U2OS, the in vitro effects on cell proliferation, apoptosis, adhesion, migration, and the angiogenic ability of human umbilical vein endothelial cells were detected using MTT, flow cytometry, Transwell, and tube formation assays, respectively. The expressions of phosphoinositide 3-kinase, phospho-Akt, total Akt, and vascular endothelial growth factor in human umbilical vein endothelial cells were detected using western blot assay.Results: Lentivirus with epidermal growth factor-like domain 7 shRNA could not significantly affect the proliferation and apoptosis of both U2OS and human umbilical vein endothelial cells, whereas the knockdown of epidermal growth factor-like domain 7 in U2OS could significantly inhibit the migration, adhesion, and angiogenic ability of co-cultured human umbilical vein endothelial cells. In addition, the expressions of phosphoinositide 3-kinase, phospho-Akt, and vascular endothelial growth factor in human umbilical vein endothelial cells decreased after co-culturing with epidermal growth factor-like domain 7-knockdown U2OS.Conclusion: Epidermal growth factor-like domain 7-knockdown U2OS cells inhibit the migration, adhesion, and angiogenesis of co-cultured human umbilical vein endothelial cells by diminishing phosphoinositide 3-kinase, Akt signaling pathway activity and vascular endothelial growth factor expression.

Keywords

• Adhesion, angiogenesis, co-culture, epidermal growth factor-like domain 7, migration, osteosarcoma

Kaynakça

1. 1. Siclari VA, Qin L. Targeting the osteosarcoma cancer stem cell. J Orthop Surg Res 2010;5:78.
2. 2. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;18;285:1182-6.
3. 3. Yang Q, Zhang S, Kang M, Dong R, Zhao J. Synergistic growth inhibition by sorafenib and cisplatin in human osteosarcoma cells. Oncol Rep 2015;33:2537-44.
4. 4. Grignani G, Palmerini E, Dileo P, Asaftei SD, D’Ambrosio L, Pignochino Y, et al. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol 2012;23:508-16.
5. 5. Scharf VF, Farese JP, Coomer AR, Milner RJ, Taylor DP, Salute ME, et al. Effect of bevacizumab on angiogenesis and growth of canine osteosarcoma cells xenografted in athymic mice. Am J Vet Res 2013;74:771-8.
6. 6. Luo W, Shao C, Li N, Zhang F, Guo S, Duan Z, et al. Expression of epidermal growth factor-like domain 7 correlates with clinicopathological features of osteosarcoma. Am J Transl Res 2015;7:1236-45.
7. 7. Freeman SS, Allen SW, Ganti R, Wu J, Ma J, Su X, et al. Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors. Cancer 2008;113:1453-61.
8. 8. Pahl JH, Ruslan SE, Buddingh EP, Santos SJ, Szuhai K, Serra M, et al. Anti-EGFR Antibody Cetuximab Enhances the Cytolytic Activity of Natural Killer Cells toward Osteosarcoma. Clin Cancer Res 2012;18:432-41.

9. 9. Wu H, Muscato NE, Gonzalez A, Shyr Y. An EGFR and AKT Signaling Pathway was Identified with Mediation Model in Osteosarcomas Clinical Study. Biomark Insights 2007;2:469-76.
10. 10. Shen X, Han Y, Xue X, Li W, Guo X, Li P, et al. Epidermal growth factor-like domain 7 promotes cell invasion and angiogenesis in pancreatic carcinoma. Biomed Pharmacother 2016;77:167-175.
11. 11. Luo BH, Xiong F, Wang JP, Li JH, Zhong M, Liu QL, et al. Epidermal Growth Factor-Like Domain-Containing Protein 7 (EGFL7) Enhances EGF Receptor-AKT Signaling, Epithelial-Mesenchymal Transition, and Metastasis of Gastric Cancer Cells. PLoS ONE 2014;9:e99922.
12. 12. Bishop MW, Janeway KA. Emerging concepts for PI3K/mTOR inhibition as a potential treatment for osteosarcoma. F1000Res 2016:5.
13. 13. Tsubaki M, Satou T, Itoh T, Imano M, Ogaki M, Yanae M, et al. Reduction of metastasis, cell invasion, and adhesion in mouse osteosarcoma by YM529/ONO5920-induced blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathway. Toxicol Appl Pharmacol 2012;259:402-10.
14. 14. Wu J, Wu X, Zhong D, Zhai W, Ding Z, Zhou Y. Short Hairpin RNA (shRNA) Ether à go-go 1 (Eag1) inhibition of human osteosarcoma angiogenesis via VEGF/PI3K/AKT signaling. Int J Mol Sci 2012;13:12573-83.
15. 15. Zhao J, Zhang ZR, Zhao N, Ma BA, Fan QY. VEGF silencing inhibits human osteosarcoma angiogenesis and promotes cell apoptosis via PI3K/AKT signaling pathway. Int J Clin Exp Med 2015;8:12411-7.
16. 16. Shen X, Han Y, Xue X, Li W, Guo X, Li P, et al. Epidermal growth factor-like domain 7 promotes cell invasion and angiogenesis in pancreatic carcinoma. Biomed Pharmacother 2016;77:167-75.
17. 17. Xu HF, Chen L, Liu XD, Zhan YH, Zhang HH, Li Q, et al. Targeting EGFL7 expression through RNA interference suppresses renal cell carcinoma growth by inhibiting angiogenesis. Asian Pac J Cancer Prev 2014;15:3045-50.
18. 18. Huang C, Yuan X, Li Z, Tian Z, Zhan X, Zhang J, et al. VE-statin/Egfl7 siRNA inhibits angiogenesis in malignant glioma in vitro. Int J Clin Exp Pathol 2014;7:1077- 84.
19. 19. Schmidt M, Paes K, De Mazière A, Smyczek T, Yang S, Gray A, et al. EGFL7 regulates the collective migration of endothelial cells by restricting their spatial distribution. Development 2007;134:2913-23.
20. 20. Pinte S, Soncin F. EGFL7 promotes tumor escape from immunity. Oncoimmunology 2012;1:375-6.
21. 21. Parker LH, Schmidt M, Jin SW, Gray AM, Beis D, Pham T, et al. The endothelialcell-derived-secreted factor EGFL7 regulates vascular tube formation. Nature 2004;428:754-8.
22. 22. Soncin F, Mattot V, Lionneton F, Spruyt N, Lepretre F, Begue A, et al. VE-statin, an endothelial repressor of smooth muscle cell migration. EMBO J 2003;22:5700-11.
23. 23. Fitch MJ, Campagnolo L, Kuhnert F, Stuhlmann H. EGFL7, a novel epidermal growth factor-domain gene expressed in endothelial cells. Dev Dyn 2004;230:316- 24.
24. 24. Freeman BB, Daw NC, Geyer JR, Furman WL, Stewart CF. Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients. Cancer Invest 2006;24:310-7.
25. 25. Zhang J, Yu XH, Yan YG, Wang C, Wang WJ. PI3K/Akt signaling in osteosarcoma. Clin Chim Acta 2015;444:182-92.
26. 26. Zhao Y, Qiu GX. Relationship between vascular endothelial growth factor expression and angiogenesis in osteosarcoma. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2001;23:619-22.
27. 27. Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL. Insulinlike growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 2002;277:38205-11.
28. 28. Kang J, Rychahou PG, Ishola TA, Mourot JM, Evers BM, Chung DH. N-myc is a novel regulator of pi3k-mediated VEGF expression in neuroblastoma. Oncogene 2008;27:3999-4007.